ExpreS2ion Biotech, listed on Nasdaq First North, is developing a first-in-class immunotherapy targeting HER2-positive and HER2-low breast cancers—forms of the disease that affect millions of women worldwide and often resist existing treatments.
Breast cancer remains a major global health challenge, with 2.3 million diagnoses and over 685,000 deaths each year. The HER2-targeting drug market alone exceeds €10 billion annually, offering both a strong medical and commercial opportunity.
ExpreS2ion’s novel therapy uses a virus-like particle (VLP) vaccine that stimulates a polyclonal immune response against all four domains of the HER2 receptor, unlike current therapies that typically target just one. Preclinical studies showed powerful tumor inhibition and complete prevention of tumor growth in animal models, even where standard drugs had failed. Early human data has confirmed strong immune activation with no safety concerns so far.
The company’s strategy is well explained by their CFO Keith Alexander. Watch his presentation from the 16th of September 2025 below:
Opportunity for investors, TO 11 warrant open for exercise
The warrant TO 11 is trading on Nasdaq First North until 30 September. This provides investors with an alternative method for investing in Expres2ion. Forty (40) warrants are required to subscribe for one (1) new share at a subscription price of 14.65 SEK.
The warrants are partially secured through a 61 % top down guarantee. Among the participants are private investors Stefan Lundgren, Peter Nilsson and John Moll, who comment on their commitment
”We have previously chosen to invest in several fund raisings in ExpreS2ion, including before and in connection with the IPO, and we are pleased to once again support the Company. Our participation in this top guarantee reflects our confidence in ExpreS2ion’s pipeline and its unique ExpreS2 platform. By committing to this structure, we aim to provide stability during the warrant exercise period and to signal continued investor interest in the Company.”
Summarised terms for the warrants of series TO 11
- Exercise period: 18 September – 2 October 2025.
- Proceeds at full subscription: SEK 11.8 million
- Forty (40) warrants of series TO 11 will be required to subscribe for one (1) new share in the Company.
- Exercise price: SEK 14.65 per share.
- Last day for trading: 30 September 2025.
Links and presentations
INVESTOR PRESENTATION DECK (from Aktiespararnas event)
This material has been prepared on behalf of ExpreS2ion Biotech for marketing purposes and is not and should not be considered an offer. Trading in securities always involves risk. Past performance is no guarantee of future returns. Investments in securities can increase or decrease in value, and there is no guarantee that you will recover your invested capital. Employees of Nyemissioner.se and Finance Lab may own shares or have other financial exposure to the company.
